德康医疗 DXCM

Mr. Kevin R. Sayer, C.P.A., Executive Chairman of the Board, Career Highlights: Executive Chair of the Board since 2026, and Chairman of the Board since 2018 , CEO of Dexcom from 2015 to 2025, and a Dexcom executive since 2011 , Former CFO of Biosensors International Group, Ltd. , Former CFO of Specialty Laboratories, Inc. , Former CFO of MiniMed, Inc., and former VP and General Manager of Medtronic MiniMed after the acquisition of MiniMed by Medtronic. Education: Bachelor's and Master's degrees in Accounting and Information Systems, Brigham Young University , Certified Public Accountant (inactive).

Mr. Jacob S. Leach, Director, President and Chief Executive Officer, Career Highlights: President and CEO of Dexcom since January 2026, setting the company's business strategy and vision to empower all people to take control of their health through transformative glucose biosensing technology , Previously served as Dexcom's President and Chief Operating Officer (May to December 2025), prior to that EVP, Chief Operating Officer (2022 to May 2025), and prior to that Chief Technology Officer (2018 to 2022) , Since 2004, has supported all major technology advancements, including the development of the first commercial Dexcom CGM system, and all subsequent generations of Dexcom biosensing solutions. Other Directorships - Current: SenesTech, Inc., a birth control solutions provider for managing rodent populations company, from 2020 to present. Other Professional Experience and Community Involvement: Currently serves on the Board of Directors at AdvaMed , Executive Committee member for the San Diego Economic Development Corporation. Education: B.Sc. in Electrical Engineering with a minor in Biomedical Engineering, University of California, Los Angeles.

Jereme Sylvain, the Company's EVP, Chief Financial Officer, to the role of EVP, Chief Operating Officer and Chief Financial Officer, effective September 14, 2026. Jereme Sylvain has served as our Chief Financial Officer since March 2021, and has served as our Chief Accounting Officer since March 2020. Prior to his role as Chief Financial Officer, Mr. Sylvain served as our Senior Vice President, Finance and Chief Accounting Officer since March 2020, and joined Dexcom in September 2018 as our Vice President, Finance and Corporate Controller. Prior to joining Dexcom, Mr. Sylvain held various positions at NuVasive, Inc., including Vice President, Corporate Controller and Chief Accounting Officer from August 2016 to September 2018 and Vice President, Corporate Controller from March 2014 to August 2016. Prior to joining NuVasive, Inc. Mr. Sylvain held the role of Senior Director, Finance with Thermo Fisher Scientific, where he was responsible for global accounting for the life sciences solutions group. Mr. Sylvain joined Thermo Fisher Scientific in February 2014, following its acquisition of Life Technologies Corporation. From July 2007 to February 2014, Mr. Sylvain held multiple finance and accounting roles at Life Technologies and its predecessor, Invitrogen Corporation. Prior to joining Invitrogen, Mr. Sylvain worked for the public accounting firm Ernst & Young LLP. Mr. Sylvain obtained his Certified Public Accounting license after receiving a B.A. in Finance from Arizona State University and a M.S. in Accountancy from the University of Notre Dame.

Jon Coleman has served as our Executive Vice President and Chief Commercial Officer since March 2025. From 2008 to 2023, Mr. Coleman held various roles at Masimo Corporation, a global medical technology company, including President, Worldwide OEM & Global Health from August 2020 to October 2023, President, Worldwide Sales, Professional Services, Medical Affairs, & OEM, from August 2017 to July 2020, President, Worldwide Sales, Professional Services, & Medical Affairs from March 2011 to July 2017, and President, International from August 2008 to February 2011. From October 2007 to August 2008, Mr. Coleman was President and Chief Executive Officer of You Take Control, Inc., a healthcare information technology start-up company. He served as General Manager, Americas of Taigus Group International, a supplier of mobile computing cases and accessories, from March 2006 to February 2007. From March 1994 to February 2006, he held progressive leadership positions with Pfizer, Inc., ultimately as its as Vice President and General Manager, Canada & Caribbean Region. Mr. Coleman holds a M.B.A. from Harvard Business School, and a B.A. in International Relations from Brigham Young University.

Michael Brown is Executive Vice President and Chief Legal Officer at Dexcom, where he has worldwide responsibility for all legal and intellectual property matters. Before joining Dexcom in January 2022, Mr. Brown was a partner at DLA Piper, from January 2017 until January 2022, where he served as outside general counsel to companies, advised on important business and legal issues, assisted with corporate governance and executed mergers and acquisitions and financings. Prior to DLA Piper, he was a partner at Stradling Yocca Carlson & Rauth, where he represented emerging and public technology, life science and other growth companies. Prior to Stradling Yocca Carlson & Rauth, Mr. Brown served as outside General Counsel for several high-growth companies. Mr. Brown earned his J.D. from the University of Virginia School of Law and his B.A. from the University of Washington. Mr. Brown is a board member of Riding on Insulin, a non-profit organization that connects the global diabetes community through action sports.

Sadie Stern has served as our Executive Vice President and Chief Human Resources Officer since September 2020. From October 2017 to September 2020, Ms. Stern was employed by 3D Systems Corporation, most recently as Executive Vice President, People and Culture. From January 2012 until October 2017, Ms. Stern served as Senior Director, Human Resources of Qualcomm. Ms. Stern has also worked at LG Electronics and The Walt Disney Company, and received a Bachelor of Arts in English from San Diego State University and a Masters of Arts in Higher Education from the University of Denver.

Ms. Renee D. Gala, Independent Director, Career Highlights: President and Chief Executive Officer of Jazz Pharmaceuticals PLC, a global biopharmaceutical company, since August 2025 , President and Chief Operating Officer of Jazz from 2023 to 2025 overseeing the company's global business operations, as well as corporate strategy , Executive Vice President and Chief Financial Officer of Jazz from 2020 to 2023, responsible for company's financial operations, corporate strategy and corporate development. , Chief Financial Officer of GRAIL, Inc., a private healthcare company focused on the early detection of cancer, from January to June 2019 , Senior Vice President and Chief Financial Officer of Theravance Biopharma, Inc. from December 2014 to January 2019. Other Directorships - Current: Jazz Pharmaceuticals PLC, a publicly-traded pharmaceuticals company, since 2025. Other Professional Experience and Community Involvement: Previous member of the board of directors at: Gossamer Bio, Inc., where she chaired the audit committee, from 2018 to 2024, Gyroscope Therapeutics from 2020 to 2021, Concept Therapeutics, Inc. from 2016 to 2019. Education: B.S. in Mathematics, Vanderbilt University, MBA, Columbia Business School.

Dr. Euan A. Ashley, Independent Director, Career Highlights: Chair of the Department of Medicine, Stanford University since 2024, and Associate Dean, Stanford University from 2019 to 2024 , Co-Director, Stanford Medicine Catalyst from 2019 to present , Professor of Medicine, Genetics, and Biomedical Data Science, Stanford University from 2006 to present , Founder, Center for Inherited Cardiovascular Disease, Stanford University since 2009. Other Directorships - Current: AstraZeneca Plc, a biotechnology company, from 2020 to present. Other Professional Experience and Community Involvement: Leadership in research institutions and private organizations , Guidance on medical technology and healthcare innovations. Education: B.Sc. in Physiology, University of Glasgow , MB ChB, University of Glasgow , D.Phil., University of Oxford , Cardiology fellowship training, Stanford University.

Mr. Mark G. Foletta, Lead Independent Director, Career Highlights: Former Executive Vice President and Chief Financial Officer of Tocagen, Inc. from 2017 to 2020 , Former Senior Vice President and Chief Financial Officer of Amylin Pharmaceuticals until its acquisition by Bristol Myers Squibb from 2000 to 2012, overseeing capital structure and investor communications. Other Directorships - Current: AMN Healthcare Services, a publicly traded healthcare workforce solutions provider, since 2012 (Board Chair) , Enanta Pharmaceuticals, a publicly traded pharmaceutical company, since 2020 (Chair of Audit Committee). Other Professional Experience and Community Involvement: Member of the Corporate Directors Forum. Education: B.A. in Business Economics, UC Santa Barbara.

Mr. Kyle Malady, Independent Director, Career Highlights: Executive Vice President and CEO of Verizon Business, overseeing services to 99% of the Fortune 500 in more than 120 countries, since 2023 , Executive Vice President of Global Networks and Technology and Chief Technology Officer at Verizon from 2018 to 2023, running America's leading wireless network, the largest residential fiber broadband and vast global IP backbone , Head of Core Engineering and Operations within the Global Network and Technology organization at Verizon from 2012 to 2018, overseeing the launch of 5G , Vice President of New Product Development at Verizon from 2005 to 2012. Other Professional Experience and Community Involvement: Chairman of CTIA, the wireless industry's trade organization, since August 2025 , Serves on the President's National Security Telecommunications Advisory Council (NSTAC) , Manages Caelens Fund, a charity that raises money to provide free cardiac surgeries for children in developing countries. Education: B.S. in Mechanical Engineering, University of Bridgeport , MBA in Finance, NYU Stern School of Business.

Ms. Rimma Driscoll, Independent Director, Career Highlights: More than two decades of global executive leadership spanning strategy, global business development, M&A, global marketing, innovation, commercial operations, and strategic alliances across the human and animal health sectors, while residing in the United States and European Union , Currently serves as EVP and Head of Global Strategy, Portfolio Marketing and Business Development, Global BioDevices and Platinum Performance at Zoetis, the world's leading animal health company , SVP, Business Development, Business Integration and Strategic Alliances at Zoetis from 2020 to 2022 , VP, Business Development and Commercial Alliances at Zoetis from 2016 to 2020. Other Directorships - Current: Pumpkin Insurance, a preventative care and pet insurance company, from 2023 to present. Other Professional Experience and Community Involvement: World 50 Strategy Group. Education: B.S. in Chemistry, Bowling Green State University , MBA, Xavier University.

Mr. Richard A. Collins, Independent Director, Career Highlights: , Chief Executive Officer for UnitedHealthcare's Northeast Region and President, Director, and/or Chairman of numerous UnitedHealthcare subsidiaries including Oxford Health Plans, Mid Atlantic Medical Services and UHC Insurance Company of New York from 2011 to 2013 , President - Individual Line of Business and Chairman and CEO of Golden Rule Financial Company from 2005 to 2012 , Held additional leadership positions in pricing, underwriting and healthcare economics at UnitedHealthcare. Other Professional Experience and Community Involvement: Former Board Chair of Fairbanks Hospital in Indianapolis, IN , Former Board Chair of The Nature Conservancy-Indiana , Former director of the UnitedHealthcare Children's Foundation , Former director of the Council for Affordable Health Insurance , Former Board Leadership Fellow of the National Association of Corporate Directors (NACD) , Volunteer Staff Member, Researcher and Collector, Florida Museum of Natural History, Invertebrate Zoology Collections. Education: B.S., Maine Maritime Academy , Executive development program at Harvard University's John F. Kennedy School of Government.

Mr. Nicholas Augustinos, Independent Director, Career Highlights: President and CEO of Aver, Inc. dba Enlace Health, a company specializing in value-based reimbursement analytics and payment solutions, from 2015 to 2018 , Senior Vice President for Health Information Services and Strategy at Cardinal Health, Inc. from 2011 to 2015 , Held various roles of increasing responsibility at Cisco Systems, Inc., the global leader in networking solutions and telemedicine, from 2005 to 2011 , Extensive consulting and managerial experience to Health Care Organizations and Insurance Companies Other Professional Experience and Community Involvement: Committee experience include Technology, Audit, Governance, and Investment. , Previous Board Member of Aver , Previous Board member of the California Health Care Foundation (CHCF) - Endowed Foundation , Previous Board Member of Audax Health Solutions - Acquired by United Healthcare , Healtheon-WebMD , Deloitte Consulting , Healthcare Delivery Administration. Education: B.Sc. in Mechanical Engineering, King's College London , MBA, University of Michigan.

Ms. Bridgette P. Heller, Independent Director, Career Highlights: Executive Vice President and President of Nutricia, the Specialized Nutrition Division of Danone, from 2016 to 2019 , Executive Vice President of Merck & Co., Inc. and President of Merck Consumer Care from 2010 to 2015 , President of Johnson & Johnson's Global Baby Business Unit from 2007 to 2010 and President of its Global Baby, Kids, and Wound Care business from 2005 to 2007 , Roles of increasing responsibility at Kraft Foods from 1985 to 2002, ultimately serving as Executive Vice President and General Manager for the North American Coffee Portfolio. Other Directorships - Current: , Aramark, a U.S. publicly traded food service and facilities provider, from 2020 to present , Integral Ad Science, a global media measurement and optimization company, from 2021 to 2025 , Novartis, an innovative medicines company, from 2020 to present , Newman's Own (Private). Other Professional Experience and Community Involvement: ,Currently leading the Shirley Proctor Puller Foundation, a nonprofit dedicated to generating better educational outcomes for underserved children in St. Petersburg, Florida. Education: ,B.A. in Economics and Computer Studies, Northwestern University ,MBA, Northwestern University.

Mr. Steven R. Altman, Independent Director, Career Highlights: Former Vice Chairman of Qualcomm and a member of Qualcomm's executive committee from 2011 to 2014 , President of Qualcomm from 2005 to 2011 , Executive Vice President of Qualcomm from 1997 to 2005 , President of Qualcomm Technology Licensing from 1995 to 2005. Other Directorships - Current: Brain Corporation (Private) , Yembo, Inc. (Private) , Amionx, Inc. (Private). Other Professional Experience and Community Involvement: Former local board member and active supporter of Breakthrough T1D (formerly JDRF). Education: B.A. in Political Science and Administration, Northern Arizona University , J.D., University of San Diego School of Law.

The board appointed Glenn S. Boehnlein as a director, effective 10th September 2026. Mr. Boehnlein is a highly accomplished healthcare executive and finance leader with more than 20 years of experience in the medical technology industry. Mr. Glenn Boehnlein most recently served as Vice President and Chief Financial Officer of Stryker Corporation from 2016 to 2025 and subsequently served as an advisor to Stryker's Chief Executive Officer from 2025 to 2026. Prior to serving as Chief Financial Officer of Stryker, Mr. Boehnlein held several senior finance leadership positions within the company, including Chief Financial Officer and Vice President of Stryker's MedSurg and Neurotechnology Group from 2011 to 2015 and Chief Financial Officer of the Endoscopy Division from 2003 to 2010. Earlier in his career, he served as Chief Financial Officer of MyPrimeTime, a media company, and was a Partner at Arthur Andersen LLP, where he led the firm's San Francisco Technology Industry Practice. Mr. Boehnlein currently serves on the Board of Directors of Inogen, Inc., a publicly traded medical technology company focused on respiratory health solutions, where he serves as Chair of the Audit Committee. In addition, he serves on the Board of Directors of Agilent Technologies, Inc., a publicly traded analytical and clinical laboratory technologies company. He also serves on the board of Sutter Health, one of the nation's leading integrated healthcare systems. Mr. Boehnlein received bachelor's and master's degrees in professional accountancy from Mississippi State University.

Mr. Rick Osterloh, Independent Director, Career Highlights: Current Senior Vice President, Platform & Devices at Google since 2016, leading a unified group spanning Android, Google Play, Chrome, and Google's Devices & Services portfolio (Pixel, Nest, Fitbit) , President of Motorola Mobility from 2014 to 2016 and SVP, Product Management & GM Premium Products, Motorola Mobility from 2012 to 2014 overseeing global product strategy and operations during Motorola's transition under Google and subsequently Lenovo , VP, Product & Design at Skype from 2010 to 2012 , Earlier roles at Motorola, Amazon, and consulting experience at Kleiner Perkins Caufield & Byers and Deloitte. Other Professional Experience and Community Involvement: Former Member of the Board of Directors of Lytro Inc., producing the first commercially available light-field cameras , Member of the Board of Directors of Positive Coaching Alliance from 2015 to 2021, a youth sports organization , Member of the Board of Directors of First Republic Bank from Q4 2022 - Q2 2023 and member of the Cybersecurity/Technology and Compensation Committees. Education: B.S. and M.S. in Industrial Engineering, Stanford University , M.B.A., Stanford University.

On February 26, 2026, the Board of Directors of DexCom, Inc., pursuant to the Amended and Restated Bylaws of the Company, increased the size of the Board to twelve directors and appointed Albert F. (Rick) Osterloh, IV as a director effective immediately. Mr. Osterloh is a highly accomplished technology executive with more than 20 years of leadership experience across consumer hardware, platform strategy and large-scale product operations. He currently serves as Senior Vice President, Platforms & Devices at Google, where he leads a unified group spanning the company's portfolio of advanced consumer technologies. This includes Android, Google Play, Chrome, and Google's Devices and Services Portfolio-Pixel phones, Google Nest smart home devices, and Fitbit wearables. Under his leadership, Google has integrated its portfolio to align and accelerate the company's advanced product capabilities across hardware, software and artificial intelligence. Mr. Rick Osterloh serves as Senior Vice President, Platform & Devices at Google, leading a unified group spanning Android, Google Play, Chrome, and Google's Devices & Services Portfolio (Pixel, Nest, Fitbit), a position he has held since 2016. Prior to this, Mr. Osterloh held additional senior leadership roles across consumer technologies. He served as President of Motorola Mobility from 2014-2016, and Senior Vice President, Product Management & GM Premium Products, Motorola Mobility from 2012-2014, overseeing global product strategy and operations during Motorola's transition under Google and subsequently Lenovo. Prior to this, Mr. Osterloh served as Vice President, Product & Design at Skype from 2010-2012 and held earlier roles at Motorola, Amazon, Kleiner Perkins Caulfield & Byers and Deloitte. Mr. Osterloh received bachelor's and master's degrees in Industrial Engineering from Stanford University. He also obtained an MBA from Stanford Graduate School of Business.